PRESS RELEASE published on 08/05/2024 at 18:49, 3 months 15 days ago Inside Information / Other news releases Sophie Boissard reappointed as CEO of Clariane Group for a 5-year term. Board of Directors shows full confidence in her leadership. Clariane Group aims for balanced development and value creation CEO Renewal Value Creation Sophie Boissard Clariane Group
BRIEF published on 06/26/2024 at 18:45, 4 months 24 days ago Clariane Finalizes Disposal of "Les Essentielles" to Odalys Disposal Clariane Odalys Les Essentielles Duval Group
PRESS RELEASE published on 06/26/2024 at 18:40, 4 months 24 days ago Inside Information / Operations of the issuer (acquisitions, sales...) Clariane confirms the disposal of its activity "Les Essentielles" to Odalys, a subsidiary of the Duval Group, involving 18 residences and part of its strategic investment reallocation plan Investment Disposal Clariane Odalys Les Essentielles
BRIEF published on 06/21/2024 at 10:25, 5 months ago Crossing of thresholds by Holding Malakoff Humanis Actions Crossing Thresholds CLARIANE SE Korian Malakoff Humanis
BRIEF published on 06/14/2024 at 11:36, 5 months 7 days ago Crossing of thresholds by Flat Footed LLC in Clariane SE Voting Rights Capital Crossing Thresholds Flat Footed LLC CLARIANE SE
PRESS RELEASE published on 06/01/2024 at 08:51, 5 months 20 days ago Terms of availability of prospectuses Clariane announces approved prospectus for capital increase on Euronext Paris. Subscription price at 2.60 euros per new share. Capital increase subject to shareholder approval on 10 June 2024 Euronext Paris Shareholder Approval Capital Increase Prospectus Clariane
BRIEF published on 06/01/2024 at 08:48, 5 months 20 days ago Korian files an amendment to its 2023 Universal Registration Document AMF ESG Growth Registration Document Clariane
PRESS RELEASE published on 06/01/2024 at 08:43, 5 months 20 days ago Terms of availability of a registration document or its updates Clariane announces the availability of an amendment to the 2023 Universal Registration Document filed with the AMF, detailing updates on financial performance and strategic objectives for 2023-2026 Financial Performance Amendment Strategic Objectives 2023 Universal Registration Document Clariane
BRIEF published on 05/29/2024 at 12:08, 5 months 23 days ago Crossing thresholds at Clariane SE AMF Participations Crossing Thresholds CLARIANE SE Public Sector Pension Investment Board
BRIEF published on 05/21/2024 at 08:37, 6 months ago Clariane Announces Medium-Term Strategic Plan and €1.5 Billion Refinancing Refinancing Organic Growth ESG Commitments Clariane Medium-Term Plan
Published on 11/21/2024 at 13:00, 26 minutes ago Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 26 minutes ago Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 26 minutes ago Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 13:00, 26 minutes ago Nextech3D.ai Spin-Out Rebrands as FOTOgpt.ai to Usher in a New Era of AI-Powered Photography
Published on 11/21/2024 at 13:00, 26 minutes ago Clean Air Metals Announces Positive Results from Innovative Seismic Survey at the Escape Deposit Down-Plunge Extension
Published on 11/21/2024 at 12:35, 51 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 11 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 06:58, 6 hours 28 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 6 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 19 hours 41 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 19 hours 41 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 5 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
